Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Current Assets for 4 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 431.69% to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, up 431.69% year-over-year, with the annual reading at $15.0 million for FY2025, N/A changed from the prior year.
  • Current Assets for Q4 2025 was $23.4 million at Neuphoria Therapeutics, up from $14.0 million in the prior quarter.
  • The five-year high for Current Assets was $29.9 million in Q2 2022, with the low at $4.4 million in Q4 2024.
  • Average Current Assets over 4 years is $15.7 million, with a median of $14.5 million recorded in 2025.
  • The sharpest move saw Current Assets plummeted 55.15% in 2023, then surged 431.69% in 2025.
  • Over 4 years, Current Assets stood at $29.9 million in 2022, then tumbled by 55.15% to $13.4 million in 2023, then crashed by 67.25% to $4.4 million in 2024, then soared by 431.69% to $23.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $23.4 million, $14.0 million, and $15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.